|
gptkbp:instanceOf
|
gptkb:small_molecule
gptkb:drug
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EA01
|
|
gptkbp:brand
|
gptkb:Jakafi
gptkb:Jakavi
|
|
gptkbp:CASNumber
|
941678-49-5
|
|
gptkbp:contraindication
|
severe hepatic impairment
active serious infection
|
|
gptkbp:developedBy
|
gptkb:Incyte
gptkb:Novartis
|
|
gptkbp:drugClass
|
gptkb:Janus_kinase_inhibitor
|
|
gptkbp:eliminationHalfLife
|
3 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C17H18N6O
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
JAK1 inhibitor
JAK2 inhibitor
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
dizziness
headache
hypertension
neutropenia
thrombocytopenia
|
|
gptkbp:synonym
|
gptkb:INCB018424
|
|
gptkbp:usedFor
|
gptkb:myelofibrosis
gptkb:polycythemia_vera
gptkb:graft-versus-host_disease
|
|
gptkbp:bfsParent
|
gptkb:JAK2_mutation
gptkb:myelofibrosis
gptkb:polycythemia_vera
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ruxolitinib
|